Clinical Scorecard: SPECTRA Data Support 4D-150 in DME
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | Dual transgene with aflibercept and RNAi targeting VEGF-C |
| Target Population | Patients with diabetic macular edema |
| Care Setting | In-office procedure via intravitreal injection |
Key Highlights
- Phase 2 SPECTRA trial focused on safety and dose determination
- No intraocular inflammation (IOI) events reported
- 16-week prophylaxis therapy with Durezol was administered
- Achieved a 9.7 letter increase in visual acuity at high dose
- Decrease in central subfield thickness showed dose response
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with diabetic macular edema receiving 4D-150
Intravitreal injection is a viable delivery method
Clinical Best Practices
- Monitor for intraocular inflammation during treatment
- Consider prophylaxis therapy with Durezol
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.